End stage renal disease serum contains a specific renal cell growth factor

L. H. Klotz, C. Kulkarni, Gordon Mills

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

End stage renal disease (ESRD) kidneys display abnormal growth characterized by a continuum of cystic disease, adenoma and carcinoma. This study evaluates the hypothesis that serum of patients with ESRD contains increased amounts of a growth factor which specifically induces proliferation of renal cells. ESRD sera compared to sera from normal controls induced a two to three-fold increase in the proliferative rate of renal cell carcinoma cell lines and normal kidney explants compared to cell lines from other sites. The increased proliferative activity of ESRD sera on renal cells was paralleled by an increase in cytosolic free calcium. The growth factor activity was encoded by a polypeptide of between 15 and 30 kd. The activity of ESRD sera on renal cells was not mimicked or inhibited by epidermal growth factor, basic fibroblast growth factor and platelet derived growth factor indicating that the renal cell specific growth factor activity in ESRD is different from these factors.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalJournal of Urology
Volume145
Issue number1
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Chronic Kidney Failure
Intercellular Signaling Peptides and Proteins
Kidney
Serum
Cell Line
Platelet-Derived Growth Factor
Fibroblast Growth Factor 2
Renal Cell Carcinoma
Epidermal Growth Factor
Adenoma
Cell Proliferation
Calcium
Carcinoma
Peptides
Growth

Keywords

  • renal cell carcinoma, end stage renal disease

ASJC Scopus subject areas

  • Urology

Cite this

End stage renal disease serum contains a specific renal cell growth factor. / Klotz, L. H.; Kulkarni, C.; Mills, Gordon.

In: Journal of Urology, Vol. 145, No. 1, 01.01.1991, p. 156-160.

Research output: Contribution to journalArticle

Klotz, L. H. ; Kulkarni, C. ; Mills, Gordon. / End stage renal disease serum contains a specific renal cell growth factor. In: Journal of Urology. 1991 ; Vol. 145, No. 1. pp. 156-160.
@article{3759f063a9494d74997241c5620e1b64,
title = "End stage renal disease serum contains a specific renal cell growth factor",
abstract = "End stage renal disease (ESRD) kidneys display abnormal growth characterized by a continuum of cystic disease, adenoma and carcinoma. This study evaluates the hypothesis that serum of patients with ESRD contains increased amounts of a growth factor which specifically induces proliferation of renal cells. ESRD sera compared to sera from normal controls induced a two to three-fold increase in the proliferative rate of renal cell carcinoma cell lines and normal kidney explants compared to cell lines from other sites. The increased proliferative activity of ESRD sera on renal cells was paralleled by an increase in cytosolic free calcium. The growth factor activity was encoded by a polypeptide of between 15 and 30 kd. The activity of ESRD sera on renal cells was not mimicked or inhibited by epidermal growth factor, basic fibroblast growth factor and platelet derived growth factor indicating that the renal cell specific growth factor activity in ESRD is different from these factors.",
keywords = "renal cell carcinoma, end stage renal disease",
author = "Klotz, {L. H.} and C. Kulkarni and Gordon Mills",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "145",
pages = "156--160",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - End stage renal disease serum contains a specific renal cell growth factor

AU - Klotz, L. H.

AU - Kulkarni, C.

AU - Mills, Gordon

PY - 1991/1/1

Y1 - 1991/1/1

N2 - End stage renal disease (ESRD) kidneys display abnormal growth characterized by a continuum of cystic disease, adenoma and carcinoma. This study evaluates the hypothesis that serum of patients with ESRD contains increased amounts of a growth factor which specifically induces proliferation of renal cells. ESRD sera compared to sera from normal controls induced a two to three-fold increase in the proliferative rate of renal cell carcinoma cell lines and normal kidney explants compared to cell lines from other sites. The increased proliferative activity of ESRD sera on renal cells was paralleled by an increase in cytosolic free calcium. The growth factor activity was encoded by a polypeptide of between 15 and 30 kd. The activity of ESRD sera on renal cells was not mimicked or inhibited by epidermal growth factor, basic fibroblast growth factor and platelet derived growth factor indicating that the renal cell specific growth factor activity in ESRD is different from these factors.

AB - End stage renal disease (ESRD) kidneys display abnormal growth characterized by a continuum of cystic disease, adenoma and carcinoma. This study evaluates the hypothesis that serum of patients with ESRD contains increased amounts of a growth factor which specifically induces proliferation of renal cells. ESRD sera compared to sera from normal controls induced a two to three-fold increase in the proliferative rate of renal cell carcinoma cell lines and normal kidney explants compared to cell lines from other sites. The increased proliferative activity of ESRD sera on renal cells was paralleled by an increase in cytosolic free calcium. The growth factor activity was encoded by a polypeptide of between 15 and 30 kd. The activity of ESRD sera on renal cells was not mimicked or inhibited by epidermal growth factor, basic fibroblast growth factor and platelet derived growth factor indicating that the renal cell specific growth factor activity in ESRD is different from these factors.

KW - renal cell carcinoma, end stage renal disease

UR - http://www.scopus.com/inward/record.url?scp=0026077975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026077975&partnerID=8YFLogxK

M3 - Article

C2 - 1984082

AN - SCOPUS:0026077975

VL - 145

SP - 156

EP - 160

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -